Many people equate a conversation about hospice as being told they must give up. However, more than 1 million people across the nation have learned just the opposite. They’ve been touched by the National Hospice and Palliative Care Organization’s “Moments of Life: Made Possible by Hospice” campaign since its launch on May 15, 2014. The campaign’s intent is to debunk this myth, and show that hospice focuses on compassionate, person-centered care, which enables special moments and memories at the end of life for patients and loved ones.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7154752-national-hospice-and-palliative-care-organization-nhpco-moments-of-life-psa/
Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine today, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59399-phoenix-children-s-hospital-visionary-institute-of-molecular-medicine
LUNGevity, the nation’s leading lung cancer-focused nonprofit organization today launched a new mobile application designed to make understanding and living with lung cancer less daunting and considerably more manageable. The new Lung Cancer Navigator mobile app provides lung cancer patients with access to the latest medical and treatment information related to their specific lung cancer diagnosis, and serves as a convenient hub for organizing customized care and support networks, asking questions, describing and tracking symptoms, and managing multiple medications.
To view the multimedia release go to:
http://www.multivu.com/players/English/7865551-lungevity-lung-cancer-navigator-app/
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.
Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Over 10,000 patients, caregivers, healthcare professionals, policy makers and the general public from 136 countries have signed the world's only Global Atrial Fibrillation Patient Charter calling for government action to help prevent millions of people from dying or becoming disabled by a stroke caused by Atrial Fibrillation (AF).
People can learn about AF and stroke, and read and sign the Charter, which is available in 22 languages, on the Campaign website,www.signagainststroke.com.
To view Multimedia News Release, go to http://www.multivu.com/players/English/57497-sign-against-stroke/
Research shows that patients who don’t consistently follow their regular medication regimen are at risk for death or hospitalization. During American Pharmacists Month in October, American Pharmacists Association (APhA) Foundation is launching the Align My Refills campaign to help patients and caregivers maintain their medication regimen with patient resources and the aid of their local pharmacist.
To view Multimedia News Release, go to: http://www.multivu.com/players/English/7337851-american-pharmacists-association-foundation-align-my-refills-campaign/
More than 80,000 healthcare workers and their communities from across the country and around the world joined together in the Medline Pink Glove Dance for breast cancer online video competition. After a hard-fought dance battle, the online votes are in and Medline is pleased to name Geisinger Health System, Danville, Pa., as the winner. As a result, $25,000 will be donated to their charity of choice, the American Cancer Society, providing free transportation for treatment to central Pennsylvania breast cancer patients in need. Additionally, Medline and participating hospitals will donate another $1 million to the National Breast Cancer Foundation and various local breast cancer charities nationwide. More than $2.2 million has been donated through the campaign and Medline Foundation since 2005.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64450-medline-pink-glove-dance-video-competition-winners-breast-cancer-education
ZapBoomBang Studios releases its inaugural project today: an original song on iTunes that was created in partnership with a local nonprofit, a GRAMMY- winning producer, and a handful of award-winning artists. It’s Out There Waiting will be sold on iTunes for $1.99 with a companion digital booklet about the making of the song. In addition, the It’s Out There Waiting music video can be purchased on iTunes for $1.99. All proceeds from iTunes sales will be donated to the children’s nonprofit Purple Songs Can Fly, who co-created the single. The song and digital booklet can be purchased at http://itunes.apple.com/us/album/its-out-there-waiting-feat./id571241651?i=571241851. The It’s Out There Waiting music video can be found at http://itunes.apple.com/us/music-video/its-out-there-waiting-music/id573793381.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58824-zapboombang-purple-songs-can-fly-song-to-benefit-children-with-cancer
The European Head and Neck Society (EHNS) today announces European-wide ‘Early Diagnosis Days’ taking place on Wednesday 24 September as part of this year’s Head and Neck Cancer Awareness Week (22–26 September). This follows the success of the 2013 campaign, where nearly 100 ‘Early Diagnosis Days’ took place. More than 5,000 patients were seen by a healthcare provider in 1 day, resulting in a referral rate of approximately 5% and multiple diagnoses of the disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762527-EHNS-early-diagnosis-days/
Urgent coordinated action from national governments, medical societies and patient organizations is needed to avoid a public health crisis resulting from the tide of preventable strokes that leave many people with atrial fibrillation (AF) mentally and physically disabled or dead, every year. How Can We Avoid a Stroke Crisis in Latin America?, a report from Action for Stroke Prevention – a group of health experts from around the world - reveals the huge economic, social and personal burden of AF-related strokes across the region. Launched today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 3rd Latin America Conference, the report proposes measures to tackle stroke in patients with AF, the most common, sustained abnormal heart rhythm and a major cause of stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/strikeoutstroke/50549/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
